|
US7597886B2
(en)
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
|
US6713061B1
(en)
|
1996-03-12 |
2004-03-30 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
|
US7357927B2
(en)
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
|
WO1997033904A1
(en)
|
1996-03-12 |
1997-09-18 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
|
US6689579B1
(en)
|
1996-10-25 |
2004-02-10 |
Human Genome Sciences, Inc. |
Polynucleotides encoding neutrokine-α
|
|
US6812327B1
(en)
|
1996-10-25 |
2004-11-02 |
Human Genome Sciences, Inc. |
Neutrokine-alpha polypeptides
|
|
US8212004B2
(en)
|
1999-03-02 |
2012-07-03 |
Human Genome Sciences, Inc. |
Neutrokine-alpha fusion proteins
|
|
AU5705898A
(en)
*
|
1996-12-17 |
1998-07-15 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
CA2232743A1
(en)
*
|
1997-04-02 |
1998-10-02 |
Smithkline Beecham Corporation |
A tnf homologue, tl5
|
|
EP1012292A1
(en)
*
|
1997-06-06 |
2000-06-28 |
Regeneron Pharmaceuticals, Inc. |
Ntn-2 member of tnf ligand family
|
|
EP0991759A1
(en)
*
|
1997-06-06 |
2000-04-12 |
Regeneron Pharmaceuticals, Inc. |
Ntn-2 member of tnf ligand family
|
|
AU9376498A
(en)
*
|
1997-09-05 |
1999-03-22 |
University Of Washington |
Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
|
|
TR200000654T2
(tr)
*
|
1997-09-12 |
2000-07-21 |
Apotech R & D Sa |
KAY-Yeni bir bağışıklık sistemi proteini.
|
|
CA2310987A1
(en)
*
|
1997-11-26 |
1999-06-03 |
Eli Lilly And Company |
Tnf ligand family gene
|
|
AU2093499A
(en)
*
|
1997-12-30 |
1999-07-19 |
Chiron Corporation |
Members of tnf and tnfr families
|
|
US6297367B1
(en)
|
1997-12-30 |
2001-10-02 |
Chiron Corporation |
Polynucleotide encoding TNFL1
|
|
WO2001060397A1
(en)
|
2000-02-16 |
2001-08-23 |
Genentech, Inc. |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
GB9828628D0
(en)
*
|
1998-12-23 |
1999-02-17 |
Glaxo Group Ltd |
Novel ligand
|
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
|
CZ303272B6
(cs)
*
|
1999-01-07 |
2012-07-11 |
Zymogenetics, Inc. |
Farmaceutický prostredek obsahující fúzní protein, izolovaná molekula polynukleotidu, expresní vektor, kultivovaná bunka, zpusob prípravy polypeptidu a izolovaný polypeptid
|
|
CZ299819B6
(cs)
*
|
1999-01-25 |
2008-12-03 |
Biogen Idec Ma Inc. |
Farmaceutické kompozice obsahující protilátky specifické pro rozpustný BAFF
|
|
US20030095967A1
(en)
|
1999-01-25 |
2003-05-22 |
Mackay Fabienne |
BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
|
|
US6475986B1
(en)
*
|
1999-02-02 |
2002-11-05 |
Research Development Foundation |
Uses of THANK, a TNF homologue that activates apoptosis
|
|
CN100439499C
(zh)
*
|
1999-02-23 |
2008-12-03 |
人体基因组科学有限公司 |
Neutrokine-α和Neutrokine-α剪接变体
|
|
EP1860190A3
(en)
*
|
1999-02-23 |
2008-03-12 |
Human Genome Sciences, Inc. |
Neutrokine-alpha and neutrokine-alpha splice variants
|
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
|
AU779402B2
(en)
|
1999-04-12 |
2005-01-20 |
Genentech Inc. |
Tumor necrosis factor homologs and nucleic acids encoding the same
|
|
US20030022233A1
(en)
*
|
1999-04-30 |
2003-01-30 |
Raymond G. Goodwin |
Methods of use of the taci/taci-l interaction
|
|
WO2000068378A1
(en)
*
|
1999-05-06 |
2000-11-16 |
National Jewish Medical And Research Center |
Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
|
|
EP1194555B1
(en)
|
1999-06-28 |
2012-09-26 |
Genentech, Inc. |
Methods for making apo-2 ligand using divalent metal ions
|
|
HK1043608B
(en)
|
1999-08-17 |
2007-12-07 |
Biogen Ma Inc. |
Baff receptor (bcma), an immunoregulatory agent
|
|
UA74798C2
(uk)
|
1999-10-06 |
2006-02-15 |
Байоджен Айдек Ма Інк. |
Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
|
|
EP1259544B1
(en)
|
2000-02-11 |
2011-08-24 |
Biogen Idec MA Inc. |
Heterologous polypeptide of the tnf family
|
|
US6969519B2
(en)
|
2000-03-10 |
2005-11-29 |
Human Genome Sciences, Inc. |
Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17)
|
|
PT2857516T
(pt)
|
2000-04-11 |
2017-08-28 |
Genentech Inc |
Anticorpos multivalentes e utilizações dos mesmos
|
|
US6926898B2
(en)
|
2000-04-12 |
2005-08-09 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
AU2001263114A1
(en)
|
2000-05-12 |
2001-11-26 |
Amgen Inc |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
|
EP1294949A4
(en)
|
2000-06-15 |
2004-08-25 |
Human Genome Sciences Inc |
HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
|
|
AU2001268427B2
(en)
|
2000-06-16 |
2007-03-29 |
Glaxosmithkline Intellectual Property Limited |
Antibodies that immunospecifically bind to blys
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
US7220840B2
(en)
|
2000-06-16 |
2007-05-22 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator protein
|
|
WO2002009755A2
(en)
|
2000-07-27 |
2002-02-07 |
Genentech, Inc. |
Apo-2l receptor agonist and cpt-11 synergism
|
|
EP1309718A4
(en)
*
|
2000-08-15 |
2004-08-25 |
Human Genome Sciences Inc |
Neutrokine-alpha and neutrokine-alpha splice variant
|
|
AU2001288301A1
(en)
|
2000-08-18 |
2002-03-04 |
Human Genome Sciences, Inc. |
Binding polypeptides and methods based thereon
|
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
|
AU2002238052A1
(en)
|
2001-02-20 |
2002-09-04 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
|
HU229910B1
(hu)
|
2001-05-11 |
2014-12-29 |
Amgen Inc Thousand Oaks |
A TALL-1-hez kötõdõ peptidek és rokon molekulák
|
|
PL403488A1
(pl)
|
2001-05-24 |
2013-07-08 |
Zymogenetics, Inc. |
Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
|
|
MXPA03010747A
(es)
|
2001-05-25 |
2004-03-02 |
Human Genome Sciences Inc |
Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
|
|
JP4509570B2
(ja)
|
2001-07-03 |
2010-07-21 |
ジェネンテック， インコーポレイテッド |
ヒトｄｒ４抗体及びその使用法
|
|
AR035119A1
(es)
|
2001-08-16 |
2004-04-14 |
Lilly Co Eli |
Anticuerpos humanos antagonistas anti-htnfsf13b
|
|
EP2348043A1
(en)
|
2001-10-02 |
2011-07-27 |
Genentech, Inc. |
APO-2 ligand variants and uses thereof
|
|
CA2476675A1
(en)
*
|
2001-10-17 |
2003-04-24 |
Human Genome Sciences, Inc. |
Neutrokine-alpha and neutrokine-alpha splice variant
|
|
US7842668B1
(en)
|
2001-11-13 |
2010-11-30 |
Genentech, Inc. |
Apo-2 ligand/trail formulations
|
|
CA2466054C
(en)
|
2001-11-13 |
2012-01-03 |
Genentech, Inc. |
Apo-2 ligand/trail formulations
|
|
US7741285B2
(en)
|
2001-11-13 |
2010-06-22 |
Genentech, Inc. |
APO-2 ligand/trail formulations
|
|
CA2841097A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin and g-csf fusion proteins
|
|
WO2004001009A2
(en)
|
2002-06-24 |
2003-12-31 |
Genentech, Inc. |
Apo-2 ligand/trail variants and uses thereof
|
|
US20050249671A9
(en)
*
|
2002-12-23 |
2005-11-10 |
David Parmelee |
Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
|
|
EP1608730B1
(en)
|
2003-03-28 |
2013-11-06 |
Biogen Idec MA Inc. |
Truncated baff receptors
|
|
ES2537738T3
(es)
|
2003-06-05 |
2015-06-11 |
Genentech, Inc. |
Terapia de combinación para trastornos de células B
|
|
US20050255560A1
(en)
*
|
2003-11-21 |
2005-11-17 |
Zeren Gao |
Ztnf11, a tumor necrosis factor
|
|
WO2005075511A1
(en)
*
|
2004-01-29 |
2005-08-18 |
Genentech, Inc. |
Variants of the extracellular domain of bcma and uses thereof
|
|
WO2006002472A1
(en)
|
2004-07-02 |
2006-01-12 |
Bio-Layer Pty Ltd |
Use of metal complexes
|
|
ES2365719T3
(es)
|
2004-08-06 |
2011-10-10 |
Genentech, Inc. |
Ensayos y procedimientos que utilizan biomarcadores.
|
|
CN101061238B
(zh)
|
2004-08-06 |
2013-11-20 |
健泰科生物技术公司 |
使用生物标志的测定法和方法
|
|
ATE535611T1
(de)
|
2004-09-15 |
2011-12-15 |
Kowa Co |
Verfahren zum screening des baff-suppressors oder inhibitors
|
|
CN101087807A
(zh)
|
2004-10-05 |
2007-12-12 |
健泰科生物技术公司 |
治疗血管炎的方法
|
|
NZ583905A
(en)
|
2004-10-13 |
2011-12-22 |
Univ Washington |
Use of BAFF to Treat Sepsis
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
AU2005318086B2
(en)
|
2004-12-23 |
2011-07-07 |
Merck Serono Sa |
BCMA polypeptides and uses thereof
|
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
|
KR20080056714A
(ko)
|
2005-08-09 |
2008-06-23 |
지모제넥틱스, 인코포레이티드 |
ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법
|
|
US8808696B2
(en)
|
2005-08-09 |
2014-08-19 |
Ares Trading S.A. |
Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
|
|
BRPI0615997A8
(pt)
|
2005-08-16 |
2018-05-22 |
Genentech Inc |
método para prever a sensibilidade de uma amostra de célula ou tecido, método para induzir apoptose em uma amostra de célula ou tecido e método de tratamento de uma disfunção
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
KR20080074120A
(ko)
|
2005-10-13 |
2008-08-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
CA2629306A1
(en)
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
|
WO2007123765A2
(en)
|
2006-03-31 |
2007-11-01 |
Human Genome Sciences Inc. |
Neutrokine-alpha and neutrokine-alpha splice variant
|
|
WO2007134326A2
(en)
|
2006-05-15 |
2007-11-22 |
Ares Trading S.A. |
Methods for treating autoimmune diseases using a taci-ig fusion molecule
|
|
DK2346995T3
(en)
|
2008-09-26 |
2019-02-11 |
Tocagen Inc |
GENETERIVE VECTORS AND CYTOSINDEAMINASES
|
|
EP2376120A2
(en)
|
2008-11-25 |
2011-10-19 |
Biogen Idec MA Inc. |
Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
JP5996429B2
(ja)
|
2009-09-03 |
2016-09-21 |
ジェネンテック， インコーポレイテッド |
関節リウマチの治療、診断及びモニターするための方法
|
|
MX361929B
(es)
|
2010-11-19 |
2018-12-19 |
Eisai R&D Man Co Ltd Star |
Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
|
|
RU2013140975A
(ru)
|
2011-02-28 |
2015-04-10 |
Дженентек, Инк. |
Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
|
|
WO2013116287A1
(en)
|
2012-01-31 |
2013-08-08 |
Genentech, Inc. |
Anti-ig-e m1' antibodies and methods using same
|
|
CN103421113B
(zh)
*
|
2012-05-22 |
2018-01-19 |
武汉华鑫康源生物医药有限公司 |
抗BLyS抗体
|
|
EP2909324B1
(en)
|
2012-10-25 |
2020-02-26 |
Tocagen Inc. |
Retroviral vector with mini-promoter cassette
|
|
PH12022550138A1
(en)
|
2013-03-13 |
2023-03-06 |
Amgen Inc |
Proteins specific for baff and b7rp1 and uses thereof
|
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
|
DE102014018663A1
(de)
|
2014-12-13 |
2015-03-05 |
Heinz Kiefer |
Nachweis von vermehrungsfähigen Zellen zur Überprüfung von Arzneimittel-Wirkstoffangaben bei Zulassungsverfahren
|
|
AR104368A1
(es)
|
2015-04-03 |
2017-07-19 |
Lilly Co Eli |
Anticuerpos biespecíficos anti-cd20- / anti-baff
|
|
EP3694870A1
(en)
|
2017-10-10 |
2020-08-19 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
|
US12202882B2
(en)
|
2020-05-08 |
2025-01-21 |
Alpine Immune Sciences, Inc. |
APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
|
|
AU2022269139A1
(en)
|
2021-05-07 |
2023-11-16 |
Alpine Immune Sciences, Inc. |
Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
|
|
CN113238061B
(zh)
*
|
2021-07-09 |
2021-10-01 |
中南大学湘雅医院 |
以cd180阴性b细胞指示重症肌无力病情的试剂盒及应用
|
|
IL319997A
(en)
|
2022-10-04 |
2025-06-01 |
Alpine Immune Sciences Inc |
Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases
|
|
CN119799684B
(zh)
*
|
2024-12-27 |
2026-02-03 |
杭州微新生物科技有限公司 |
一种靶向无害梭菌的抗菌蛋白及其制备方法与应用
|